Ursodeoxycholic acid and severe COVID-19 outcomes in people with liver disease: a cohort study using the OpenSAFELY platform
Costello, R. E.; Waller, K. M.; Smith, R.; Mells, G. F.; Wong, A. Y.; Schultze, A.; Mahalingasivam, V.; Herrett, E.; Zheng, B.; Lin, L.-Y.; Mehrkar, A.; Bacon, S. C.; Goldacre, B.; Tomlinson, L. A.; Tazare, J.; Rentsch, C. T.
Show abstract
Biological evidence suggests ursodeoxycholic acid (UDCA) - a common treatment of cholestatic liver disease - may prevent severe COVID-19 outcomes. With the approval of NHS England, we conducted a population-based cohort study using primary care records, linked to death registration data and hospital records through the OpenSAFELY-TPP platform. We estimated the hazard of COVID-19 hospitalisation or death between 1 March 2020 and 31 December 2022, comparing UDCA treatment to no UDCA treatment in a population with indication. Of 11,320 eligible individuals, 642 were hospitalised or died with COVID-19 during follow-up, 402 (63%) events among UDCA users. After confounder adjustment, UDCA was associated with a 21% (95% CI 7%-33%) relative reduction in the hazard of COVID-19 hospitalisation or death, consistent with an absolute risk reduction of 1.3% (95% CI 1.0%-1.6%). Our findings support calls for clinical trials investigating UDCA as a preventative measure for severe COVID-19 outcomes.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.